Home › Bladder Cancer › Oklahoma
Bladder Cancer clinical trials in Oklahoma
12 studies for Bladder Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03866382Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07061964Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06770582Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07097142Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07000084A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - OKC, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.